Literature DB >> 3091516

Arachidonic acid metabolism in human neutrophils: lack of effect of cyclosporine A.

O H Nielsen, K Bukhave, I Ahnfelt-Rønne, J Elmgreen.   

Abstract

The metabolism of arachidonic acid (AA) in human neutrophils was studied by incorporation of 1-14C-AA, removal of excess 1-14C-AA, and stimulation of radiolabelled cells with A23187. Radiolabelled lipids were quantitated by extraction, thin-layer chromatography, autoradiography, and laser densitometry. Following 5 h of incubation with 1-14C-AA, the maximum amount of radioactivity was located in triglycerides, 70%, and phospholipids, 30%. Activation of the cells with calcium ionophore A23187 led to release of free AA, 58%, whereas AA-metabolites revealed mainly lipoxygenase (arachidonate 5 lipoxygenase, E.C. 1. 13. 11. 34) activity, 5-HETE 13%, LTB4 5%, with only small amounts of cyclooxygenase (prostaglandin synthase, E.C. 1. 14. 99. 1) metabolites, HHT 2%. Intra-assay coefficient of variation for release of metabolites was approximately 15%. A potent immunosuppressive agent, cyclosporine A (CS-A) was shown to be without any effect in AA-release and metabolism. This method is applicable to studies of both basic cell function in human disease and to further immunopharmacological investigations.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3091516     DOI: 10.1016/0192-0561(86)90126-8

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  11 in total

1.  Enhanced capacity for release of leucotriene B4 by neutrophils in rheumatoid arthritis.

Authors:  J Elmgreen; O H Nielsen; I Ahnfelt-Rønne
Journal:  Ann Rheum Dis       Date:  1987-07       Impact factor: 19.103

2.  Effects of antirheumatic drugs on endogenous arachidonate metabolism and chemotaxis in human neutrophil granulocytes.

Authors:  O H Nielsen; I Ahnfelt-Rønne; J Elmgreen
Journal:  Agents Actions       Date:  1989-01

3.  Abnormal metabolism of arachidonic acid in chronic inflammatory bowel disease: enhanced release of leucotriene B4 from activated neutrophils.

Authors:  O H Nielsen; I Ahnfelt-Rønne; J Elmgreen
Journal:  Gut       Date:  1987-02       Impact factor: 23.059

4.  Effects of cyclosporin A and FK506 on ischemia/reperfusion-induced neutrophil infiltration in the cat.

Authors:  P Kubes; J Hunter; D N Granger
Journal:  Dig Dis Sci       Date:  1991-10       Impact factor: 3.199

5.  Inhibition of human neutrophils by auranofin: chemotaxis and metabolism of arachidonate via the 5-lipoxygenase pathway.

Authors:  J Elmgreen; I Ahnfelt-Rønne; O H Nielsen
Journal:  Ann Rheum Dis       Date:  1989-02       Impact factor: 19.103

Review 6.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

7.  Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid.

Authors:  O H Nielsen; K Bukhave; J Elmgreen; I Ahnfelt-Rønne
Journal:  Dig Dis Sci       Date:  1987-06       Impact factor: 3.199

8.  Source of endogenous arachidonate and 5-lipoxygenase products in human neutrophils stimulated by bradykinin and A23187.

Authors:  O H Nielsen; K Bukhave; I Ahnfelt-Rønne; J Rask-Madsen
Journal:  Gut       Date:  1988-03       Impact factor: 23.059

9.  Serum interferon activity in inflammatory bowel disease. Arachidonic acid release and lipoxygenation activated by alpha-class interferon in human neutrophils.

Authors:  O H Nielsen; J Elmgreen; I Ahnfelt-Rønne
Journal:  Inflammation       Date:  1988-04       Impact factor: 4.092

Review 10.  Role of Arachidonic Acid and Its Metabolites in the Biological and Clinical Manifestations of Idiopathic Nephrotic Syndrome.

Authors:  Stefano Turolo; Alberto Edefonti; Alessandra Mazzocchi; Marie Louise Syren; William Morello; Carlo Agostoni; Giovanni Montini
Journal:  Int J Mol Sci       Date:  2021-05-21       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.